Open Access Articles- Top Results for Paromomycin


Systematic (IUPAC) name
Clinical data
AHFS/ monograph
MedlinePlus a601098
  • US: N (Not classified yet)
Oral, intramuscular
Pharmacokinetic data
Bioavailability None
Metabolism None
Half-life ?
Excretion Fecal
1263-89-4 7pxY
PubChem CID 441375
DrugBank DB01421 7pxY
ChemSpider 390117 7pxY
ChEBI CHEBI:7934 7pxY
ChEMBL CHEMBL370143 7pxN
Chemical data
Formula C23H47N5O18S
615.629 g/mol
 14pxN (what is this?)  (verify)

Paromomycin is an aminoglycoside antibiotic, first isolated from Streptomyces krestomuceticus in the 1950s.[1] It was discovered by Parke Davis now Pfizer and introduced as Humatin in 1960.[2] It is also called monomycin and aminosidine;[3]

It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.[4]

Medical uses

It is an antibiotic used to treat intestinal infections such as cryptosporidiosis[5] and amoebiasis,[6] and other diseases such as leishmaniasis.[7] Paromomycin was demonstrated to be effective against cutaneous leishmaniasis in clinical studies in the USSR in the 1960s, and in trials with visceral leishmaniasis in the early 1990s.[3]

The route of administration is intramuscular injection and capsule. Paromomycin topical cream with or without gentamicin is an effective treatment for ulcerative cutaneous leishmaniasis, according to the results of a phase-3, randomized, double-blind, parallel group–controlled trial.[8]


Paromomycin is a protein synthesis inhibitor in nonresistant cells by binding to 16S ribosomal RNA.[9] This broad-spectrum antibiotic soluble in water, is very similar in action to neomycin. Antimicrobial activity of paromomycin against Escherichia coli and Staphylococcus aureus has been shown.[10]


  1. ^ Davidson RN, den Boer M, Ritmeijer K (2008). "Paromomycin". Transactions of the Royal Society of Tropical Medicine and Hygiene 103 (7): 653–60. PMID 18947845. doi:10.1016/j.trstmh.2008.09.008. 
  2. ^ Marshall Sittig (1988). Pharmaceutical Manufacturing Encyclopedia 1. Noyes Publications. p. 1166. ISBN 9780815511441. 
  3. ^ a b Neal RA, Murphy AG, Olliaro P, Croft SL (1994). "Aminosidine ointments for the treatment of experimental cutaneous leishmaniasis". Transactions of the Royal Society of Tropical Medicine and Hygiene 88 (2): 223–5. PMID 8036682. doi:10.1016/0035-9203(94)90307-7. 
  4. ^ "WHO Model List of Essential Medicines" (PDF). World Health Organization. October 2013. Retrieved 2014-04-22. 
  5. ^ Sweetman S, ed. (2002). Martindale: The Complete Drug Reference (33rd ed.). London: Pharmaceutical Press. ISBN 978-0-85369-499-1. 
  6. ^ "paromomycin" at Dorland's Medical Dictionary
  7. ^ Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK (2007). "Injectable paromomycin for visceral leishmaniasis in India". N. Engl. J. Med. 356 (25): 2571–81. PMID 17582067. doi:10.1056/NEJMoa066536. 
  8. ^ Ben Salah A, Ben Messaoud N, Guedri E, Zaatour A, Ben Alaya N, Bettaieb J, Gharbi A, Belhadj Hamida N et al. (2013). "Topical Paromomycin with or without Gentamicin for Cutaneous Leishmaniasis". N. Engl. J. Med. 368 (6): 524–32. PMID 23388004. doi:10.1056/NEJMoa1202657. 
  9. ^ Vicens Q, Westhof E (2001). "Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site". Structure 9 (8): 647–58. PMID 11587639. doi:10.1016/S0969-2126(01)00629-3. 
  10. ^ "Paromomycin" (PDF). Toku-E. 2010-01-12. Retrieved 2012-06-11.